Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

On Monday, Germany-based Merck KGaA (OTC ... Additionally, SpringWorks’ products have the potential to help counter revenue losses from expiring drug patents and increased competition.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... estimates could grow to become a $800 million-plus product. FDA approval means that Gomekly becomes only the ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both ...

Keytruda & Other Oncology Drugs Drive Merck’s Top Line Merck’s flagship product, Keytruda, generated sales of $7.84 billion in the quarter, up 21%. Sales of the drug benefited from rapid ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...